Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation
暂无分享,去创建一个
Dawn L Hershman | Lori M Minasian | L. Minasian | J. Unger | D. Hershman | M. Fleury | Mark E Fleury | Joseph M Unger | Riha Vaidya | R. Vaidya
[1] D. Carbone,et al. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. , 2013, Clinical lung cancer.
[2] D. Petereit,et al. Involving American Indians and medically underserved rural populations in cancer clinical trials , 2009, Clinical trials.
[3] Enrollment onto breast cancer therapeutic clinical trials: a tertiary cancer center experience. , 2013, Applied nursing research : ANR.
[4] E. Elkin,et al. Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. , 2015, JAMA oncology.
[5] Moon S. Chen,et al. Overcoming barriers to cancer clinical trial accrual , 2008, Cancer.
[6] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[7] Jack Bowden,et al. A comparison of heterogeneity variance estimators in simulated random‐effects meta‐analyses , 2018, Research synthesis methods.
[8] Feng Li,et al. An Introduction to Metaanalysis , 2005 .
[9] Katherine L Kahn,et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. , 2013, Journal of oncology practice.
[10] E. Trimble,et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. , 1996, Journal of the National Cancer Institute.
[11] J. Crowley,et al. Patient income level and cancer clinical trial participation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Siminoff,et al. Barriers to therapeutic clinical trials enrollment: Differences between African-American and white cancer patients identified at the time of eligibility assessment , 2012, Clinical trials.
[13] B. Biedrzycki. Factors and outcomes of decision making for cancer clinical trial participation. , 2011, Oncology nursing forum.
[14] A. D'Amico,et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Carol L. Brown,et al. Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. , 2015, Gynecologic oncology.
[16] S. Cha,et al. Patients' attitudes and preferences about participation and recruitment strategies in clinical trials. , 2009, Mayo Clinic proceedings.
[17] M. Krasna,et al. Tracking clinical trial accrual strategies and barriers via a Web-based screening tool. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Prescott,et al. Barriers to participation in randomised controlled trials: a systematic review. , 1999, Journal of clinical epidemiology.
[19] C. Klabunde,et al. Factors influencing enrollment in clinical trials for cancer treatment. , 1999, Southern medical journal.
[20] W. G. Cochran. The combination of estimates from different experiments. , 1954 .
[21] Michael A. Gold,et al. Impact of Individual Physicians on Enrollment of Patients into Clinical Trials , 2003, American journal of clinical oncology.
[22] G. Colditz,et al. An institutional strategy to increase minority recruitment to therapeutic trials , 2013, Cancer Causes & Control.
[23] A. Kaluzny,et al. The NCI Community Cancer Centers Program , 2015 .
[24] S. Chevret,et al. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] J. Proctor,et al. A screening tool to enhance clinical trial participation at a community center involved in a radiation oncology disparities program. , 2011, Journal of oncology practice.
[26] A. Guarino,et al. Barriers exist to patient participation in clinical trials , 2005 .
[27] M. Christian,et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Cohen,et al. Barriers to clinical trial participation by older women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Gönen,et al. Impact of the National Cancer Institute Community Cancer Centers Program on Clinical Trial and Related Activities at a Community Cancer Center in Rural Nebraska. , 2016, Journal of Oncology Practice.
[30] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[31] M. Leblanc,et al. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. , 2016, JAMA oncology.
[32] Leslie Neal-Boylan,et al. Overcoming Barriers. , 2015, Journal for nurses in professional development.
[33] Amy P Abernethy,et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. , 2013, JAMA internal medicine.
[34] R. Govindan,et al. Barriers for accrual to clinical trials in adult patients (pts) with thoracic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. McCaskill-Stevens,et al. Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. , 2014, Journal of oncology practice.
[36] Robert C. Gooding,et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Iztok Hozo,et al. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. , 2008, Archives of internal medicine.
[38] Edward S. Kim,et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Sarah E. Brockwell,et al. A comparison of statistical methods for meta‐analysis , 2001, Statistics in medicine.
[40] Shari Bolen,et al. Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review , 2008, Cancer.
[41] Jan J Barendregt,et al. Meta-analysis of prevalence , 2013, Journal of Epidemiology & Community Health.
[42] C. Gross,et al. Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities , 2007, Annals of Surgical Oncology.
[43] M. Carducci,et al. Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study , 2012, Trials.
[44] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[45] J. Newhouse,et al. Econometrics in outcomes research: the use of instrumental variables. , 1998, Annual review of public health.
[46] P. Philip,et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] L. Hedges,et al. Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.
[48] S. Wolff,et al. Recruitment of African Americans to National Oncology Clinical Trials through a Clinical Trial Shared Resource , 2010, Journal of health care for the poor and underserved.
[49] R. Rosenfeld. Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[50] Stephanie Green,et al. Clinical Trials in Oncology , 1997 .
[51] Asher Mullard,et al. NCI-MATCH trial pushes cancer umbrella trial paradigm , 2015, Nature Reviews Drug Discovery.
[52] N. Petrelli. A community cancer center program: getting to the next level. , 2010, Journal of the American College of Surgeons.
[53] C. Raker,et al. Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program. , 2010, Gynecologic oncology.
[54] Lawrence J Appel,et al. Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. , 2015, JAMA.
[55] Jon D. Miller,et al. Public attitudes toward participation in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Harlan M Krumholz,et al. Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.
[57] I. Hozo,et al. Evaluation of new treatments in radiation oncology: are they better than standard treatments? , 2005, JAMA.
[58] Kumanan Wilson,et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. , 2006, The Lancet. Oncology.
[59] Sarah M. Greene,et al. Organizational barriers to physician participation in cancer clinical trials. , 2005, The American journal of managed care.
[60] Jame Abraham,et al. Barriers to recruitment of rural patients in cancer clinical trials. , 2011, Journal of oncology practice.
[61] A. Bleyer,et al. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[62] Suzanne M. Miller,et al. Barriers to clinical trial participation as perceived by oncologists and patients. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[63] J. Niland,et al. Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[64] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[65] M. Fouad,et al. Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials. , 2016, Journal of oncology practice.
[66] D. Gandara,et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] H. Sorbye,et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients , 2009, Cancer.
[68] D. Holmes,et al. Increasing minority patient participation in cancer clinical trials using oncology nurse navigation. , 2012, American journal of surgery.
[69] J. Tukey,et al. Transformations Related to the Angular and the Square Root , 1950 .
[70] G. Hortobagyi,et al. Factors associated with participation in breast cancer treatment clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] M. Simon,et al. An Educational Video to Increase Clinical Trials Enrollment among Lung Cancer Patients , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[72] Hannah R Rothstein,et al. A basic introduction to fixed‐effect and random‐effects models for meta‐analysis , 2010, Research synthesis methods.
[73] Shiraz I Mishra,et al. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. , 2006, Cancer detection and prevention.
[74] Michelle A. Mathiason,et al. Clinical trial accrual among new cancer patients at a community‐based cancer center , 2006, Cancer.
[75] C. Gotay,et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). , 2012, The oncologist.
[76] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[77] R. Govindan,et al. Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[78] K. Ding,et al. Factors influencing clinical trial enrollment among ovarian cancer patients. , 2016, Gynecologic oncology.
[79] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[80] L. Beckett,et al. An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California , 2004, Cancer journal.
[81] L. Kachnic,et al. Cancer clinical trial enrollment of diverse and underserved patients within an urban safety net hospital. , 2016, The Journal of community and supportive oncology.
[82] P. LoRusso,et al. Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit. , 1999, American journal of clinical oncology.
[83] F. Hirsch,et al. Innovative Clinical Trials: The LUNG‐MAP Study , 2015, Clinical pharmacology and therapeutics.
[84] Wolfgang Viechtbauer,et al. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model , 2005 .
[85] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] James Topping,et al. Compliance with results reporting at ClinicalTrials.gov. , 2015, The New England journal of medicine.
[87] M. Haffner. Adopting orphan drugs--two dozen years of treating rare diseases. , 2006, The New England journal of medicine.